Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078021" target="_blank" >RIV/00023001:_____/19:00078021 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11160/19:10407892
Výsledek na webu
<a href="https://reader.elsevier.com/reader/sd/pii/S105324981931407X?token=84C99B8CCF9AF13745C1E66A10E91EE1C4303F2C7F8E32EE7E2B2C6362ADCB22C71A06970C36E39AA645B16268E63B49" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S105324981931407X?token=84C99B8CCF9AF13745C1E66A10E91EE1C4303F2C7F8E32EE7E2B2C6362ADCB22C71A06970C36E39AA645B16268E63B49</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.healun.2019.02.013" target="_blank" >10.1016/j.healun.2019.02.013</a>

Jazyk výsledku
angličtina
Název v původním jazyce
Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study
Popis výsledku v původním jazyce
In this analysis, we have validated that the low-intensity anti-coagulation used in MAGENTUM-1 (INR 1.50‒1.90) results in a decreased anti-coagulant effect compared with standard intensity warfarin anti-coagulation (INR 2.0–3.0), as evidenced by the differential levels of CFX suppression, an independent method of assessing anti-coagulation intensity. The finding suggests that low-intensity warfarin anti-coagulation is reliable and feasible in selected patients supported with this type of left ventricular assist device.
Název v anglickém jazyce
Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study
Popis výsledku anglicky
In this analysis, we have validated that the low-intensity anti-coagulation used in MAGENTUM-1 (INR 1.50‒1.90) results in a decreased anti-coagulant effect compared with standard intensity warfarin anti-coagulation (INR 2.0–3.0), as evidenced by the differential levels of CFX suppression, an independent method of assessing anti-coagulation intensity. The finding suggests that low-intensity warfarin anti-coagulation is reliable and feasible in selected patients supported with this type of left ventricular assist device.

Projekt
<a href="/cs/project/NV16-27630A" target="_blank" >NV16-27630A: Markery vaskulárního zdraví u pacientů s implantovanou mechanickou srdeční podporou</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)